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ABSTRACT
Objective: This study aimed to measure and compare the effectivity and cost of the two types of ceftriaxone to determine the more cost-effective 
treatment.
Methods: In a cross-sectional analytical study, prescription and administrative financial data were retrospectively collected using the total sampling 
method. Data of 63 patients, comprising 43 and 20 patients treated with generic and patent ceftriaxone, respectively, were analyzed. The effectiveness 
of the treatment was measured in terms of the length of hospital stay of the patients. The total cost of the treatment was the total median of the costs 
of drugs, laboratory examinations, medical device usage, physician service, and hospitalization.
Results: The effectiveness of both generic and patent ceftriaxone was 4 days of hospital stay. Cost-effectiveness ratio of generic ceftriaxone was Rp 
575,937.25/day and that of patent ceftriaxone was Rp 888,601.75/day.
Conclusion: Generic ceftriaxone was more cost-effective than patent ceftriaxone.
Keywords: Cost-effectiveness analysis, Pharmacoeconomic, Typhoid fever, Ceftriaxone, Karya Bhakti Pratiwi Hospital.
INTRODUCTION
Typhoid fever is a communicable disease accounting for 22 million 
cases annually and is the cause of mortality in 216,000–600,000 people 
worldwide. Typhoid fever is an endemic disease in Indonesia [1]. 
The aim of prescribing antibiotics is to cease the bacterial growth 
and shorten the duration of signs and symptoms of the disease. 
The selection of antibiotics is based on sensitivity pattern in each 
hospital [2]. In Karya Bhakti Pratiwi Hospital, generic and branded 
antibiotics have been used as the first-line treatment for pediatric 
patients with typhoid fever since 2012. Based on the CPOB manuals, 
generic and branded medicines should have equal effectivity. However, 
the effectivity of generic and branded medicines remains different, 
as reported in a previous study [3]. This probability of a significant 
cost difference as well as effectivity difference between generic and 
branded medicines encouraged us to perform a pharmacoeconomic 
analysis of these medicines using cost-effectiveness analysis (CEA). In 
this study, CEA was used to measure and compare the effectiveness and 
cost between these two types of treatments to identify the more cost-
effective treatment.
METHODS
In this cross-sectional analytical study, secondary of prescription and 
cost administrative data of patients were retrospectively obtained [4]. 
The study was conducted at the inpatient installation of Karya Bhakti 
Pratiwi Hospital, Bogor, from February to April 2017. The study 
included all children with typhoid fever who were administered generic 
or patent ceftriaxone in 2016 and who met the inclusion criteria. Data 
were obtained using the total sampling method. Variables measured 
included medication effectivity, total medication cost, age, and sex.
Inclusion criteria were children with typhoid fever aged 1–19 years 
who were treated with generic or patent ceftriaxone. Exclusion criteria 
were patients with unclear, incomplete, or untracked medical records, 
those undergoing treatment with antibiotics other than ceftriaxone, 
and those with a change of treatment class or antibiotic type during the 
inpatient period.
Data were analyzed using Microsoft Excel and IBM Statistical Package 
for the Social Sciences 20.0., Armonk, NY: IBM Corp. with a confidence 
interval of 95% and an α=0.05. The calculation of effectivity and 
medication cost included the effectivity proportion of medications 
including the length of hospital stay and total medication cost in rupiah 
in each group of generic and patent ceftriaxone.
Total medication cost was obtained from the total cost of direct 
medical components including drugs, medical device use, laboratory 
examinations, and service in each group of generic and patent ceftriaxone.
After obtaining total medication cost, CEA was performed, which 
comprised cost-effectiveness ratio (CER), cost-effectiveness incremental 
ratio (CEIR), and sensitivity analysis. CER was obtained by comparing 
total medication cost on medication effectiveness (only in patients free 




CEIR was obtained by comparing total incremental medication cost 
with incremental effectiveness between the two ceftriaxone groups. 
The value obtained considered CEIR score, which represented the 




Two types of one-way sensitivity analyses were used in this study: Using 
simulated increase and decrease in total medication cost and using 
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maximum and minimum simulations from total medication cost. Both 
sensitivity analyses were performed with a fixed effectiveness value.
RESULTS
Based on prescription data in 2016, 167 pediatric patients used generic 
or patent ceftriaxone as treatment for typhoid fever in 2016. After 
adjusting the inclusion and exclusion criteria, the study included 63 
children. Patients’ characteristics are summarized in Table 1.
CEA
Treatment effectiveness in this study was measured in terms of the 
length of hospital stay of patients. The results of effectiveness analysis 
parameter were presented as the median length of stay of the generic 
and patent ceftriaxone groups. Based on the analysis, the median 
length of hospital stay was 4 days. Mann–Whitney U-test revealed no 
significant difference between generic and patent ceftriaxone treatment 
effectiveness in terms of the length of hospital stay (p=0.548).
The results of cost analysis using the total cost of direct medical 
components for the two groups are presented in Table 2.
Drug cost was defined as the cost of ceftriaxone used during the 
hospitalization period. The median drug cost of generic and patent 
ceftriaxone was Rp 97,000 and Rp 1,070,880, respectively. Based on 
non-parametric Mann–Whitney U-test, the p-value obtained was 0.000. 
Drug costs of generic and patent ceftriaxone were significantly different 
(p<0.05).
Laboratory examinations were performed in the diagnostic stage, 
therapy progress observation, and final results of the treatment. 
Laboratory examinations for pediatric patients with typhoid fever 
usually include the Widal test, immunochromatography test, 
and polymerase chain reaction test (3.1 [EN] Please expand the 
abbreviation). Median laboratory examination cost during the use of 
ceftriaxone was calculated and compared between the generic and 
patent ceftriaxone groups. Based on the sample data obtained from 
Information System and Management of Hospital, median laboratory 
costs for the two groups were Rp 308,000 and Rp 365,000, respectively. 
Based on non-parametric Mann–Whitney U-test, the p-value obtained 
was 0.963 (p>0.05), indicating that laboratory examination cost was 
not significantly different between the two groups.
Median medical device use cost during the use of ceftriaxone was 
calculated and compared between the generic and patent ceftriaxone 
groups. Medical devices included needle, syringe, infusion equipment, 
NaCl 0.9% solution, alcohol swab, bandage, mask, and gloves. Based 
on cost data stated on Information System of Hospital in each patient, 
median medical device use cost in the generic and patent ceftriaxone 
groups was Rp 87,351 and Rp 133,529, respectively. Based on 
nonparametric Mann–Whitney U-test, the p-value obtained was 0.040 
(p<0.05), indicating that medical device use cost was significantly 
different between the two groups.
Service cost included physician service cost during patients’ stay in the 
hospital. Median service cost in generic and patent ceftriaxone groups 
was Rp 130,000 and Rp 260,000, respectively. Based on non-parametric 
Table 2: Comparison of medical cost between generic and patent ceftriaxone groups





Median drug cost 97,000 1,070,880 0.000*
Median laboratory cost 308,000 365,000 0.953
Median medical device use cost 87,351 133,529 0.040*
Median service cost 130,000 260,000 0.153
Median hospitalization cost 1,555,000 1,695,000 0.170
Median total medication cost 2,303,749 3,554,407 0.000*
*significant difference
Table 1: Patient characteristics







Toddlers (0–5 years) 35 (55.55) 22 (51.16) 13 (65)
Children (>5–11 years) 25 (39.69) 18 (41.87) 7 (35)
Adolescents (>11–19 years) 3 (4.76) 3 (6.97) 0 (0)
Total 63 (100) 43 (100) 20 (100)
Sex
Male 28 (44.45) 18 (41.86) 10 (50)
Female 35 (55.55) 25 (58.14) 10 (50)
Total 63 (100) 43 (100) 20 (100)
Payment source 
Self-found 24 (38.1) 13 (30.23) 11 (55)
BPJS (National Health Insurance) 24 (38.1) 22 (51.16) 2 (20)
Private Health Insurance 15 (23.8) 8 (18.61) 7 (35)
Total 63 (100) 43 (100) 20 (100)
Treatment class
Class I 13 (20.63) 11 (25.58) 2 (10)
Class II 12 (19.04) 10 (23.25) 2 (10)
Class III 23 (36.50) 15 (34.88) 8 (40)
First Class 3 (4.76) 1 (2.32) 2 (10)
VIP Class 11 (17.49) 5 (11.65) 6 (30)
VVIP Class 1 (1.58) 1 (2.32) 0 (0)
Total 63 (100) 43 (100) 20 (100)
Length of hospital stay
Median (days) 4 4 4
Range 3–7 3–7 3–7
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Mann–Whitney U-test, the p-value obtained was 0.153 (p>0.05), 
indicating that service cost was not significantly different between the 
two groups.
Median hospitalization cost in the generic and patent ceftriaxone 
groups was Rp 1,555,000 and Rp 1,695,000, respectively. Based on 
non-parametric Mann–Whitney U-test, the p-value obtained was 0.170 
(p>0.05), indicating that hospitalization was not significantly different 
between the two groups.
Median total medication cost for patent ceftriaxone (Rp 3,554,407) 
was higher than that for generic ceftriaxone (Rp 2,303,749). Based 
on non-parametric Mann–Whitney U-test, the p-value obtained was 
0.000 (p<0.05), indicating that total medication cost was significantly 
different between the two groups. Median total medication cost for 
each medication was used further in CEA, which consisted of CER, CEIR, 
and sensitivity analysis.
CER
Mean CER was calculated by comparing median total medication 
cost with medication effectiveness in generic and patent ceftriaxone 
groups. Based on normality test, total cost data distribution was not 
normal; hence, median total medication cost used in the calculation was 
considered total medication cost. Medication effectiveness was defined 
as median length of hospital stay. The CER of each medication group is 
shown in Table 3.
CER of the generic ceftriaxone group was lower (Rp 575,937.25/
day) than that of the patent ceftriaxone group (Rp 888,601.75/day). 
Moreover, CER was calculated according to the treatment class of 
patients. CER of each medication group based on their treatment class 
is shown in Table 4.
The length of hospital stay in the generic and patent ceftriaxone 
groups was similar, showing effectiveness equality between the two 
medication groups. However, total medication cost in the generic 
ceftriaxone group was lower than that in the patent group; hence, 
generic ceftriaxone was in a dominant position in the effectiveness 
and cost table (Table 5). Meanwhile, the patent ceftriaxone group was 
in the dominant position. A clear position between the medication 
groups showed that generic ceftriaxone was more cost-effective than 
patent ceftriaxone; hence, calculation of the CEIR was not necessary. 
Subsequently, a sensitivity analysis was performed to measure 
uncertainty from various data used as well as resulting from the 
pharmacoeconomic analysis.
Sensitivity analysis
Sensitivity analysis was performed by simulating 25% or 50% increase 
and decrease in median total medication cost. The results of the 
sensitivity analysis are shown in Table 6.
The results of the sensitivity analysis showed that even though median 
total medication cost from generic ceftriaxone was decreased by 25% 
and 50% or increasing by 25% and 50%, CER of the generic ceftriaxone 
group remained lower than that of the baseline CER of the patent 
ceftriaxone group (Rp 888,601.8). Meanwhile, a significant difference 
in the CER of the patent ceftriaxone was observed only at 50% decrease 
median total medication cost, at which point the CER of the patent 
ceftriaxone group (Rp 444,300.88) became lower than the baseline CER 
of the generic ceftriaxone group (Rp 575,937.3).
DISCUSSION
Of the 63 patients in this study, 43 and 20 patients were administered 
generic or patent ceftriaxone of a brand, respectively. The analysis 
was performed by comparing total medicinal cost and treatment 
effectiveness of the generic and patent ceftriaxone groups.
Among the patients who met the inclusion criteria, the number of 
patients using generic ceftriaxone (71.67%) was more than that of 
patients using patent ceftriaxone (28.33%). This might be explained 
by the fact that a majority of patients were covered under BPJS 
health insurance (National Health Insurance), and the use of generic 
ceftriaxone was recommended according to BPJS terms and conditions 
in 2014 stated in National Formularies based on Keputusan Menkes RI 
No.328/Menkes/SK/2013 [5].
Based on the payment source type, 24 patients paid total medication 
cost independently (38.09%); 24 patients paid total medication cost 
Table 5: Effectiveness and cost of generic and patent ceftriaxone use for pediatric patients with typhoid fever
Effectiveness and cost Lower cost Same cost Higher cost
Lower effectiveness (Need CEIR calculation) Patent to generic ceftriaxone in Class II+(Domined)
Same effectiveness Overall generic to patent ceftriaxone+(Dominant) Overall patent to generic ceftriaxone+(Domine)
Higher effectiveness Generic to patent ceftriaxone in Class II+(Dominant) (Need CEIR calculation)
CEIR: Cost-effectiveness incremental ratio
Table 4: CER according to treatment class
Ceftriaxone type Treatment class Total medication cost (Rp) Length of stay CER  
(Rp/day)
Generic Class I 2,979,218 4 744,804.5
Class II 1,604,913 4 401,228.25
Class III 1,690,996 4 422,749
First Class 3,422,989 4 855,747.25
VIP Class 4,234,205 4 1,058,551.25
VVIP Class 4,703,229 4 1,175,807.25
Patent Class I 4,607,705 4 1,151,926.25
Class II 3,697,294 4.5 821,620.89
Class III 3,040,111 4 760,027.75
First Class 4,690,747 4 1,172,686.75










Generic Rp 2,303,749 4 575,937.25
Patent Rp 3,554,407 4 888,601.75
CER: Cost-effectiveness ratio
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using BPJS (38.09%), with 3 using BPJS COB, 20 using BPJS non-PBI, 
and one patient using BPJS PBI, and 15 patients (23.81%) paid total 
medicinal cost using other insurance. Patients with BPJS PBI had the 
right to avail treatment Class III. Meanwhile, patients with BPJS non-
BPI and BPJS CPB had the right to avail treatment Class I, II, or III 
depending on the premise paid. Patients with BPJS non-PBI and COB 
could propose to change for a better treatment class by paying the 
cost difference outside the BPJS premise. Based on hospital policy, 
patients hospitalized with insurance were referred to treatment 
Classes I, II, first class, VIP, and VVIP. However, room selection 
was based on patients’ need and desire. This caused the variable 
distribution of treatment classes in pediatric patients with typhoid 
fever in this study.
Karya Bhakti Pratiwi Hospital provides five types of treatment classes 
for inpatients: Class I, Class II, Class III, first class, VIP class, and 
VVIP class. Based on the treatment class type, of the 43 patients with 
typhoid fever who were administered generic ceftriaxone, 11 were 
in Class I (25.58%), 10 were in Class II (23.25%), 15 were in Class III 
(34.88%), 1 was in first class (2.32%), 5 were in VIP class (11.65%), 
and 1 was in VVIP class (2.32%). Meanwhile, of the 20 patients with 
typhoid fever who were administered patent ceftriaxone, two were in 
Class I (10.00%), two were in Class II (10%), eight were in Class III 
(40.00%), three were in first class (15.00%), and four were in VIP class 
(20.00%). Treatment cost for each class was different, which affected 
total medication cost.
The length of hospital stay was defined as the total number of days from 
the day patients was hospitalized until discharge from the hospital. 
Median length of hospital stay in patients who were administered 
generic or patent ceftriaxone was 4 days, ranging from 3 to 7 days.
Treatment effectiveness was measured in terms of the length of hospital 
stay. There was no significant difference between the ceftriaxone types 
used and treatment effectiveness in terms of the length of hospital 
stay. The results of effectiveness analyses were in agreement with the 
government policy stating that quality, efficacy, and safety should not 
be different between generic and branded drugs as well as patent drugs 
with the same active substance [6].
Analysis of CER of the generic and patent ceftriaxone groups based 
on treatment class showed that CER of the generic ceftriaxone group 
was lower than that of the patent ceftriaxone in all treatment classes. 
However, CER calculation alone was not adequate to identify the 
more cost-effective group [7-10]. Medication alternative position in 
effectiveness and cost table was determined to confirm the effectiveness 
and cost of the medications. In effectiveness and cost analysis, the cost 
was the medication cost and not the mean of effectiveness and cost.
Pharmacoeconomic analysis was performed to account for uncertainty 
from all obtained and used data. To calculate uncertainty, the cause 
of uncertainty was identified, scored, and interpreted with sensitivity 
analysis. On the basis of the results of sensitivity analysis, it can be 
concluded that before and after cost simulations, CER of the generic 
ceftriaxone group was lower than that of the patent ceftriaxone group, 
except when median total medicinal cost of patent ceftriaxone was 
decreased by 50%. This study is suggested to be taken as evaluation 
consideration for the regulator so that generic ceftriaxone can be 
taken as it is more cost-effective than branded ceftriaxone. However, 
further study is needed and if it possible, to consider other effectivity 
parameters such as number of anti-salmonella immunoglobulin M 
counted, number of decreased fever temperature, and the count of 
leukocytes. It is also suggested to consider including indirect cost and 
intangible cost in further study.
CONCLUSION
The medication effectiveness of generic ceftriaxone was equal to 
that of patent ceftriaxone, as evident by the equal median length of 
hospital stay (4 days) for both drug types. Statistically, there was no 
significant difference in medication effectiveness between generic and 
patent ceftriaxone in terms of the length of hospital stay (p=0.548). 
Median total medication cost of patent ceftriaxone was higher (Rp 
3,554,407) than that of generic ceftriaxone (Rp 2,303,749), and there 
was a statistically significant difference in medication effectiveness 
between generic and patent ceftriaxone in terms of median total 
medication cost (p=0.000). Based on CEA, generic ceftriaxone (CER: 
Rp 575,937.25/day) was more cost-effective than patent ceftriaxone 
(CER: Rp 888,601.75/day).
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